125 related articles for article (PubMed ID: 16055308)
1. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.
Fleischhacker WW; Keet IP; Kahn RS;
Schizophr Res; 2005 Oct; 78(2-3):147-56. PubMed ID: 16055308
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST).
Pijnenborg GH; Timmerman ME; Derks EM; Fleischhacker WW; Kahn RS; Aleman A
Eur Neuropsychopharmacol; 2015 Jun; 25(6):808-16. PubMed ID: 25907250
[TBL] [Abstract][Full Text] [Related]
5. Treatment of depression in first episode of schizophrenia: results from EUFEST.
Rybakowski JK; Vansteelandt K; Szafranski T; Thys E; Jarema M; Wolfgang Fleischhacker W; Kahn RS; Peuskens J;
Eur Neuropsychopharmacol; 2012 Dec; 22(12):875-82. PubMed ID: 22627166
[TBL] [Abstract][Full Text] [Related]
6. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
[TBL] [Abstract][Full Text] [Related]
7. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
[TBL] [Abstract][Full Text] [Related]
8. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
9. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.
Rybakowski JK; Vansteelandt K; Remlinger-Molenda A; Fleischhacker WW; Kahn RS; Peuskens J;
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1500-5. PubMed ID: 25085534
[TBL] [Abstract][Full Text] [Related]
10. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial.
Ceskova E; Prikryl R; Libiger J; Svancara J; Jarkovsky J
Schizophr Res; 2015 Dec; 169(1-3):303-307. PubMed ID: 26545298
[TBL] [Abstract][Full Text] [Related]
12. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.
Fleischhacker WW; Derks E; Kahn RS
Schizophr Res; 2012 Jun; 138(1):39-40. PubMed ID: 22542244
[TBL] [Abstract][Full Text] [Related]
13. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.
Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M
Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
17. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
18. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM
Neuropsychopharmacology; 2003 May; 28(5):995-1003. PubMed ID: 12700715
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
20. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
